TINAVI Medical (688277.SH): 3Q26 results review: revenue and margins under pressure; watch the pace of 4Q recovery

TINAVI Medical's 3Q26 revenue grew year on year but came in below our estimate, as slower medical-equipment tendering in 1H26 delayed revenue recognition. Gross margin declined, reflecting a lower direct-sales mix, system-mix changes and intensifying competition, and consumables margin also eased; expense control nonetheless narrowed the net loss year on year. Management reiterated its FY26 installation target and its targets of EBITDA breakeven in 2026 and core-business breakeven in 2027. Procedure volumes improved, yet competition and hospital pricing pressure remain evident across systems and consumables, and implementation of robotic-surgery charging policy is still unresolved, with most orthopedic procedures classified as "participatory execution" and provincial details pending;